-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photos
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Leisure
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In-Depth
-
Weekend
-
Lifestyle
-
Diversions
-
Movies
-
Hotels and Food
-
Special Report
-
Yes Teens!
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Futian Today
-
Advertorial
-
CHTF Special
-
Focus
-
Guide
-
Nanshan
-
Hit Bravo
-
People
-
Person of the week
-
Majors Forum
-
Shopping
-
Investment
-
Tech and Vogue
-
Junior Journalist Program
-
Currency Focus
-
Food and Drink
-
Restaurants
-
Yearend Review
-
QINGDAO TODAY
在线翻译:
szdaily -> Special Report -> 
Russia aims to approve vaccine by mid-August
    2020-07-30  08:53    Shenzhen Daily

RUSSIA intends to be the first in the world to approve a coronavirus vaccine, in less than two weeks — despite concerns about its safety, effectiveness and over whether the country has cut essential corners in development.

Russian officials told CNN they are working toward a date of Aug. 10 or earlier for approval of the vaccine, which has been created by the Moscow-based Gamaleya Institute.

It will be approved for public use, with frontline healthcare workers getting it first, they said.

Dozens of vaccine trials are underway around the world and a small number are in large-scale efficacy trials, but most developers have cautioned that much work remains before their vaccines can be approved.

While some global vaccines are in the third phase of trials, the Russian vaccine is yet to complete its second phase. Developers plan to complete that phase by Aug. 3, and then conduct the third phase of testing in parallel with the vaccination of the medical workers.

Russians scientists say the vaccine has been quick to develop because it is a modified version of one already created to fight against other diseases. That’s the approach being taken in many other countries and by other companies.

Notably, Moderna, whose vaccine is being backed by the U.S. government and which started Phase 3 testing Monday, has built its coronavirus vaccine on the backbone of a vaccine it had been developing for a related virus, MERS. While this has sped the development process, U.S. and European regulators are requiring the full complement of safety and efficacy tests for the vaccine. Russia’s defense ministry says that Russian soldiers served as volunteers in human trials. Russian officials say the drug is being fast-tracked through approval because of the global pandemic and Russia’s own severe coronavirus problem. The country now has more than 800,000 confirmed cases.

The vaccine uses human adenovirus vectors that have been made weaker so they do not replicate in the body. Unlike most vaccines in development it relies on two vectors, not one, and patients would receive a second booster shot.

(SD-Agencies)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010-2020, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@126.com